Relugolix: First Global Approval
Relugolix: First Global Approval
复制标题
DOI：
10.1007/s40265-019-01105-0
复制
发表时间：
2019-04-01
期刊：
影响因子：
11.5
通讯作者：
Markham, Anthony
中科院分区：
文献类型：
--
作者：
Markham, Anthony
Takeda和ASKA Pharmaceutical正在开发口服活性非肽类促性腺激素释放激素（GnRH）受体拮抗剂Relugolix（Relumina），用于治疗各种性激素相关疾病。Relugolix最近在日本被批准上市，用于治疗子宫肌瘤相关症状，目前正在进行评估该药物治疗子宫肌瘤相关疼痛和前列腺癌疗效的研究。本文总结了Relugolix开发过程中导致首次获批用于治疗子宫肌瘤相关症状的里程碑。
The orally active nonpeptide gonadotropin-releasing hormone (GnRH)-receptor antagonist relugolix (Relumina) is being developed by Takeda and ASKA Pharmaceutical as a treatment for various sex hormone related disorders. Relugolix was recently approved for marketing in Japan as a treatment for symptoms associated with uterine fibroids, and studies evaluating the efficacy of the drug as treatment for endometriosis-associated pain and prostate cancer are currently underway. This article summarizes the milestones in the development of relugolix leading to this first approval for the treatment of symptoms associated with uterine fibroids.